UroSpot

Oncology drugs can be a direct cause of renal insufficiency and failure during treatment*. Vascular damage, with direct toxicity to the glomerular & tubule function can cause, among others, severe electrolyte disturbance.



These renal issues caused by the interactions between cancer and the kidney may require dosage adjustment of anticancer drugs in order to avoid drug accumulation and long term side-effects.



Our full service provides a unique early warning system for oncology patients during treatment. We collect and eco-process urine of patients to avoid toxic molecules being circulated in the water supply, on top of ensuring urine data transmission via our urine collector and native application to the patient’s treatment group.

During the period of urinary elimination of the therapy molecules, our collector allows patients to urinate fully, autonomously and with dignity at home or at the hopsital without impacting the environment or people around them.

Thanks to the simple handling of our native application, patients can easily facilitate the monitoring of their treatment, thus guaranteeing a precise follow-up of their kidney’s health by their Treatment Groups.



*Source :

• http://sitegpr.com/fr/rein/en-savoir-plus/oncologie-et-insuffisance-renale/

• Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376–1384.

• Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin. Nephrol. 2010; 30:548–556.